{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T18:25:29Z","timestamp":1781375129015,"version":"3.54.1"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T00:00:00Z","timestamp":1625529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>There is limited experience of PD-1 antibody combined with other therapies in children. We aimed to explore the antitumor activity and safety of PD-1 antibody monotherapy or combination with other regimens in relapsed or refractory pediatric cancer. This is a retrospective-case study conducted in two Chinese expert centers. The primary objective of this study was to describe the overall response rate (ORR) and disease control rate (DCR). Secondary objectives included characterizing toxicities. Of the 22 pediatric patients with cancer who received PD-1 inhibitors, the median follow-up for all patients after the commencement of PD-1 therapy with or without other regimens was 12.3 months (0 - 43 months). PD-1 antibody monotherapy demonstrated antitumor activity in a population of pediatric patients with Hodgkin lymphoma (HL), with an objective response rate (ORR) and disease control rate (DCR) of 83.3% (3CR and 2PR) and 100%, respectively. However, no objective response was observed in patients with melanoma or Burkitt lymphoma evaluated in this study. We reviewed responses for patients with chemotherapy, decitabine or everolimus combination therapies with PD-1 antibodies, and found that PD-1 antibody combined with decitabine showed potential efficacy in pediatric patients with advanced embryonal rhabdomyosarcoma and lymphoepitheliomatoid-like carcinoma. There were no severe treatment-related adverse events (TRAEs) directly attributed to PD-1 antibody monotherapy in Asian pediatric patients with lower incidence of hematologic toxicity and nonhematologic toxicity. The Grade \u22653 TRAEs were attributed to the combination chemotherapy.<\/jats:p>","DOI":"10.3389\/fimmu.2021.647733","type":"journal-article","created":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T07:40:48Z","timestamp":1625557248000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Combination Therapy With Anti-PD-1 or PD-1 Antibody Alone in Asian Pediatric Patients With Relapsed or Refractory Cancer"],"prefix":"10.3389","volume":"12","author":[{"given":"Yi","family":"Que","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junting","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suying","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feifei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijun","family":"Zhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiqing","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haixia","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizhuo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,7,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2019.08.021","article-title":"Pediatric Cancer","volume":"34","author":"Baliga","year":"2020","journal-title":"Hematol\/Oncol Clin N Am"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-019-09836-y","article-title":"Compare and Contrast: Pediatric Cancer Versus Adult Malignancies","volume":"38","author":"Kattner","year":"2019","journal-title":"Cancer Metastasis Rev"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e260","DOI":"10.3346\/jkms.2018.33.e260","article-title":"Treatment Outcomes in Children and Adolescents With Relapsed or Progressed Solid Tumors: A 20-Year, Single-Center Study","volume":"33","author":"Cho","year":"2018","journal-title":"J Korean Med Sci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaw4153","article-title":"Ushering in the Next Generation of Precision Trials for Pediatric Cancer","volume":"363","author":"DuBois","year":"2019","journal-title":"Science"},{"key":"B5","doi-asserted-by":"publisher","first-page":"39","DOI":"10.3390\/ht7040039","article-title":"Precision Medicine in Pediatric Cancer: Current Applications and Future Prospects","volume":"7","author":"Ahmed","year":"2018","journal-title":"High-Throughput"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in Previously Untreated Melanoma Without BRAF Mutation","volume":"372","author":"Robert","year":"2015","journal-title":"New Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in Patients With Metastatic DNA Mismatch Repair-Deficient or Microsatellite Instability-High Colorectal Cancer (CheckMate 142): An Open-Label, Multicentre, Phase 2 Study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31827-5","article-title":"Nivolumab in Patients With Advanced Gastric or Gastro-Oesophageal Junction Cancer Refractory to, or Intolerant of, at Least Two Previous Chemotherapy Regimens (ONO-4538-12, ATTRACTION-2): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial","volume":"390","author":"Kang","year":"2017","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30671-0","article-title":"Pembrolizumab in Paediatric Patients With Advanced Melanoma or a PD-L1-Positive, Advanced, Relapsed, or Refractory Solid Tumour or Lymphoma (KEYNOTE-051): Interim Analysis of an Open-Label, Single-Arm, Phase 1-2 Trial","volume":"21","author":"Geoerger","year":"2020","journal-title":"Lancet Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30023-1","article-title":"Nivolumab in Children and Young Adults With Relapsed or Refractory Solid Tumours or Lymphoma (ADVL1412): A Multicentre, Open-Label, Single-Arm, Phase 1-2 Trial","volume":"21","author":"Davis","year":"2020","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01076-2","article-title":"Toripalimab: First Global Approval","volume":"79","author":"Keam","year":"2019","journal-title":"Drugs"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-1066-z","article-title":"Sintilimab: First Global Approval","volume":"79","author":"Hoy","year":"2019","journal-title":"Drugs"},{"key":"B13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13045-018-0693-2","article-title":"Safety and Clinical Activity With an Anti-PD-1 Antibody JS001 in Advanced Melanoma or Urologic Cancer Patients","volume":"12","author":"Tang","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30192-3","article-title":"Safety and Activity of Sintilimab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (ORIENT-1): A Multicentre, Single-Arm, Phase 2 Trial","volume":"6","author":"Shi","year":"2019","journal-title":"Lancet Haematol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.03.082","article-title":"RECIST 1.1 - Standardisation and Disease-Specific Adaptations: Perspectives From the RECIST Working Group","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur J Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1-Update and Clarification: From the RECIST Committee","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur J Cancer"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and non-Hodgkin Lymphoma: The Lugano Classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised Response Criteria for Malignant Lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 Blockade With Nivolumab in Relapsed or Refractory Hodgkin\u2019s Lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"New Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed\/Refractory Classic Hodgkin Lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative Analysis Reveals Selective 9p24.1 Amplification, Increased PD-1 Ligand Expression, and Further Induction via JAK2 in Nodular Sclerosing Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","first-page":"10.1002\/pbc.26792","DOI":"10.1002\/pbc.26792","article-title":"Pathology and Genomics of Pediatric Melanoma: A Critical Reexamination and New Insights","volume":"65","author":"Bahrami","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"11200","DOI":"10.1038\/srep11200","article-title":"TERT Promoter Mutations Are Predictive of Aggressive Clinical Behavior in Patients With Spitzoid Melanocytic Neoplasms","volume":"5","author":"Lee","year":"2015","journal-title":"Sci Rep"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/JID.2015.374","article-title":"Telomerase Expression by Aberrant Methylation of the TERT Promoter in Melanoma Arising in Giant Congenital Nevi","volume":"136","author":"Fan","year":"2016","journal-title":"J Invest Dermatol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"45704","DOI":"10.1038\/srep45704","article-title":"Genetic and Epigenetic Alterations of TERT Are Associated With Inferior Outcome in Adolescent and Young Adult Patients With Melanoma","volume":"7","author":"Seynnaeve","year":"2017","journal-title":"Sci Rep"},{"key":"B26","article-title":"Impact of Chemotherapy for Colorectal Cancer on Regulatory T-Cells and Tumor Immunity","volume":"31","author":"Maeda","year":"2011","journal-title":"Anticancer Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1080\/08923973.2018.1424897","article-title":"Chemotherapy Alters the Increased Numbers of Myeloid-Derived Suppressor and Regulatory T Cells in Children With Acute Lymphoblastic Leukemia","volume":"40","author":"Salem","year":"2018","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-2967","article-title":"Cranking the Immunologic Engine With Chemotherapy: Using Context to Drive Tumor Antigen Cross-Presentation Towards Useful Antitumor Immunity","volume":"66","author":"van der Most","year":"2006","journal-title":"Cancer Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-12-756841","article-title":"PD1 Blockade With Pembrolizumab is Highly Effective in Relapsed or Refractory NK\/T-Cell Lymphoma Failing L-Asparaginase","volume":"129","author":"Kwong","year":"2017","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2914","article-title":"Molecular Pathways: At the Crossroads of Cancer Epigenetics and Immunotherapy","volume":"21","author":"Maio","year":"2015","journal-title":"Clin Cancer Research: An Off J Am Assoc Cancer Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02151","article-title":"Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed\/Refractory Classical Hodgkin Lymphoma","volume":"37","author":"Nie","year":"2019","journal-title":"J Clin Oncol: Off J Am Soc Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"8_suppl, TPS25-TPS25","DOI":"10.1200\/JCO.2019.37.8_suppl.TPS25","article-title":"A Pilot Study of Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatric and Young Adult Patients With Relapsed and Refractory Solid Tumors or Lymphoma","volume":"37","author":"Turpin","year":"2019","journal-title":"J Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.canlet.2019.04.025","article-title":"PD-1\/PD-L1 Blockade in Paediatric Cancers: What Does the Future Hold","volume":"457","author":"Moreno-Vicente","year":"2019","journal-title":"Cancer Lett"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S124008","article-title":"Targeting the PD-1 Pathway in Pediatric Solid Tumors and Brain Tumors","volume":"10","author":"Wagner","year":"2017","journal-title":"OncoTargets Ther"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00726","article-title":"Management of Adverse Events in Cancer Patients Treated With PD-1\/PD-L1 Blockade: Focus on Asian Populations","volume":"10","author":"Yang","year":"2019","journal-title":"Front Pharmacol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.0393","article-title":"Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"15567","DOI":"10.1038\/s41598-020-72649-5","article-title":"Landscape of Immune Checkpoint Inhibitor-Related Adverse Events in Chinese Population","volume":"10","author":"Li","year":"2020","journal-title":"Sci Rep"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2019.1654303","article-title":"Durable Blockade of PD-1 Signaling Links Preclinical Efficacy of Sintilimab to its Clinical Benefit","volume":"11","author":"Wang","year":"2019","journal-title":"mAbs"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for Classical Hodgkin\u2019s Lymphoma After Failure of Both Autologous Stem-Cell Transplantation and Brentuximab Vedotin: A Multicentre, Multicohort, Single-Arm Phase 2 Trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2019.02.007","article-title":"A Phase Ib Study of Pembrolizumab as Second-Line Therapy for Chinese Patients With Advanced or Metastatic Melanoma (KEYNOTE-151)","volume":"12","author":"Si","year":"2019","journal-title":"Trans Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3922","article-title":"Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial","volume":"26","author":"Tang","year":"2020","journal-title":"Clin Cancer Research: An Off J Am Assoc Cancer Res"},{"key":"B42","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/psp4.12143","article-title":"Model-Based Population Pharmacokinetic Analysis of Nivolumab in Patients With Solid Tumors","volume":"6","author":"Bajaj","year":"2017","journal-title":"CPT: Pharmacometrics Syst Pharmacol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/15513815.2020.1764680","article-title":"PD-L1 and PD-L2 Mutations in Pediatric Hodgkin Lymphoma: Do They Have Any Prognostic Significance","author":"Gul","year":"2020","journal-title":"Fetal Pediatr Pathol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.647733\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T07:40:51Z","timestamp":1625557251000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.647733\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,6]]},"references-count":43,"alternative-id":["10.3389\/fimmu.2021.647733"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.647733","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,6]]},"article-number":"647733"}}